Compare GMGI & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMGI | OLMA |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.5M | 725.5M |
| IPO Year | N/A | 2020 |
| Metric | GMGI | OLMA |
|---|---|---|
| Price | $0.86 | $33.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $4.00 | ★ $40.50 |
| AVG Volume (30 Days) | 229.4K | ★ 8.5M |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $179,142,103.00 | N/A |
| Revenue This Year | $25.59 | N/A |
| Revenue Next Year | $14.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.24 | N/A |
| 52 Week Low | $0.70 | $2.86 |
| 52 Week High | $2.60 | $33.50 |
| Indicator | GMGI | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 82.93 |
| Support Level | $0.74 | $25.62 |
| Resistance Level | $0.84 | $33.50 |
| Average True Range (ATR) | 0.07 | 2.25 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 96.23 | 96.91 |
Golden Matrix Group Inc is an established gaming technology company. The company develops and owns online gaming IP and builds configurable and scalable white-label social gaming platforms for its international customers. The company operates in three reportable segments; MeridianBet Group, GMAG, RKings & CFAC. The MeridianBet Group segment earns majority revenue. The company operates in UK, Europe, Asia Pacific, Central and South America, Australia and Africa. It offers configurable and scalable iGaming platforms and operate some of the industry's iconic brands, including MexPlay, GM-AG, and others.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.